Is MCK a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Defensive, volume-driven distribution core, with revenue (ttm) at ~$411 billion (+7.7% YoY latest quarter). The bear case rests on the central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. Analysts covering it are spread from $845.00 to $1200.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $845.00, -15.9% from the $1004.84 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Defensive, volume-driven distribution core. Drug distribution is a non-discretionary business: prescriptions get filled in good economies and bad, and an aging population plus rising prescription volumes provide a slow, steady tailwind. The most optimistic analyst target on MCK is $1200.00, +19.4% from the $1004.84 price. That figure is only reachable if this thesis works close to its best case.

The central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. Customer concentration is real, with a few very large retail-pharmacy customers representing a big share of revenue, giving those partners negotiating leverage. Drug-pricing politics and policy (Medicare negotiation, PBM reform, importation proposals) create ongoing regulatory uncertainty. McKesson also carries a legacy of multibillion-dollar opioid-distribution settlements, and future litigation or regulatory action remains a tail risk. Execution on the Medical-Surgical separation, on integrating oncology and specialty acquisitions, and on the Option Care Health partnership adds transition risk on top of the steady core. GAAP earnings can also swing well away from adjusted figures: GAAP net income was about $614 million in the June 2026 quarter versus about $1.68 billion in the March quarter. Valuation has stretched as well, with the shares up about 21% in three months to above $1,000 and trading near 27 times trailing GAAP earnings. The most pessimistic published target is $845.00, -15.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the 'Big Three' US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Defensive, volume-driven distribution core) stalling in the reported numbers rather than in the narrative, the risk above (the central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a defensive, cash-generative distribution franchise with rising higher-margin oncology and specialty services, steady buybacks, and repeated guidance raises. The bear case is razor-thin distribution margins, heavy customer concentration, drug-pricing policy risk, and a legacy of opioid-settlement liabilities. Weigh both against your own portfolio.

McKesson is a pharmaceutical distributor and healthcare-services company. Its core business buys drugs from manufacturers and delivers them to pharmacies, hospitals, and clinics at massive scale. On top of that logistics backbone it runs higher-margin businesses in specialty and oncology services, group purchasing, and prescription-access technology. It does not manufacture the drugs it distributes.

Distribution is a high-volume, low-margin business. McKesson earns only a small fraction of each dollar of drugs it moves, mainly through fees and buy-side efficiencies rather than markups on branded medicines. That is why its roughly $411 billion of trailing revenue (as of October 2026) translates into comparatively modest operating profit, and why the mix-shift toward higher-margin services matters so much to the story. Operating margin runs near 1.35%.